<SEC-DOCUMENT>0001213900-21-011939.txt : 20210226
<SEC-HEADER>0001213900-21-011939.hdr.sgml : 20210226
<ACCEPTANCE-DATETIME>20210226090440
ACCESSION NUMBER:		0001213900-21-011939
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210224
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210226
DATE AS OF CHANGE:		20210226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OptimizeRx Corp
		CENTRAL INDEX KEY:			0001448431
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				261265381
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38543
		FILM NUMBER:		21684069

	BUSINESS ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
		BUSINESS PHONE:		248-651-6558

	MAIL ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea136604-8k_optimizerx.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
February 24, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>OptimizeRx Corporation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center">Nevada</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center">001-38543</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center">26-1265381</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction of <BR>
incorporation)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(Commission File Number)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(I.R.S. Employer <BR>
Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 66%; text-align: center">400 Water Street, Suite 200, Rochester, MI</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center">48307</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Registrant&rsquo;s telephone number, including area code: <U>248.651.6568</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; width: 100%; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center">(Former name or former address, if changed since last report)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&#9744;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&#9744;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&#9744;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&#9744;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Title of each class</B></TD>
    <TD STYLE="text-align: center; width: 2%; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Trading symbol</B></TD>
    <TD STYLE="text-align: center; width: 2%; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Name of each exchange on which registered</B></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Common Stock</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">OPRX</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Nasdaq Capital Market</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8 &ndash; Other Events</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01 Other Events</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 24, 2021, we held a conference
call to discuss our 2020 fourth quarter and year-end earnings and other matters of business, a transcript of which is furnished
herewith as Exhibit 99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in Item 8.01 of this Current
Report on Form 8-K (including Exhibit 99.1) shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities
Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;) or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 9 &ndash; Financial Statements and Exhibits</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; background-color: rgb(204,238,255)">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">99.1</TD><TD STYLE="text-align: justify"><A HREF="ea136604ex99-1_optimizerx.htm">Conference call transcript dated February 24, 2021</A></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>OptimizeRx Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Doug Baker</FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Doug Baker</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: February 26, 2021</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea136604ex99-1_optimizerx.htm
<DESCRIPTION>CONFERENCE CALL TRANSCRIPT DATED FEBRUARY 24, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>OptimizeRX
Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Fourth
Quarter and Full Year 2020 Conference Call</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>February
24, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRX Corporation - Fourth Quarter and Full Year 2020 Conference Call, February 24, 2021</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>C O R P O R A T E P A R T I C I P A
N T S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo, </B><I>Chief Executive
Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Douglas Baker, </B><I>Chief Financial
Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Steve Silvestro, </B><I>Chief Commercial
Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Miriam Paramore, </B><I>President and
Chief Strategy Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>C O N F E R E N C E C A L L P A R T
I C I P A N T S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ryan Daniels,</B> <I>William Blair &amp;
Company</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Andrew D&rsquo;Silva,</B> <I>B. Riley FBR,
Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Eric Martinuzzi,</B> <I>Lake Street
Capital Markets</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Thomas, </B><I>RBC Capital Markets</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brandon Osten,</B> Venetor Capital</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Harvey Poppel,</B> <I>Poptech, LP</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ron Chez</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sid Kapoor,</B> Silver Mount Capital</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>P R E S E N T A T I O N</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good afternoon, and thank you for joining
us today to discuss OptimizeRx Corporation&rsquo;s Fourth Quarter and Full Year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With us today is the Chief Executive Officer
of OptimizeRx, William Febbo, and the Company&rsquo;s President and Chief Strategy Officer, Miriam Paramore. They are joined by Company
Chief Financial Officer, Doug Baker, and Chief Commercial Officer, Stephen Silvestro.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now I&rsquo;d like to turn the call over to OptimizeRx
CEO, William Febbo. Sir, please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRX Corporation - Fourth Quarter and Full Year 2020 Conference Call, February 24, 2021</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Greg.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good afternoon, everyone. Thanks for joining
us today.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have record numbers which is great and
everyone&rsquo;s welcome. I&rsquo;d like to begin once again expressing our gratitude for the countless healthcare professionals across the
country, who have continued frankly to work tirelessly and selflessly in battling the pandemic and keeping us all safe, and who
are now leading the charge in administrating the vaccine to the most vulnerable and those on the front lines as they work their
way to the general population. Over the past year, the pandemic has clearly accelerated the shift towards digital health by both
physicians and patients, and especially for physicians looking to keep their operations going and adapt to the new widespread challenge
of delayed treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to a recent study done by the
American Medical Association, nearly 90% of doctors in the U.S. see significant advantage in using digital tools to engage with
and treat patients. Moreover, over half of physicians in the study say they&rsquo;re looking for more access to clinically relevant data
and workflow improvements at the point-of-care where they&rsquo;re treating their patients. If there is any silver lining around the
pandemic, it would be how the compelling and important benefits from the adoption of telehealth, and especially the digital health
solutions like we provide, have been accelerated by at least five to ten years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As one of the first major movers in the
point-of-care of digital health space, we&rsquo;ve been able to reap the benefit of this industry transformation, as well as be a leader
in setting the highest standards for reaching physicians and patients in a way which supports decision making around care. This
includes delivering the most innovative solutions that better support patients and healthcare providers with affordability, access
and adherence. While the shift was already well underway before the pandemic, as evidenced by growth over the last few years, we
are now witnessing an even more astonishing acceleration towards digital solutions. This has transformed and vastly expanded our
total addressable market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In fact, in Q4, we more than doubled our
topline while generating positive GAAP net income. This was largely a result of a strong organic revenue growth. We see this combination
of organic growth and innovation for solutions will drive us forward in 2021 and beyond. We also practice what we preach. That
is, we have continued to drive our own internal digital transformation as a Company. Earlier last year, we restructured our organization
to align with what McKinsey refers to as the digital factory or DF model. This model has been shown to bring products to market
faster, do more with existing resources, and create a dramatically reimagined experience for clients. It can also reduce tech development
costs by a third, and most importantly, attract the great talent required to compete in a digital world, and boy did that pay off
last year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Powered by our own digital transformation,
we successfully broadened our platform to encompass more solutions that enabled doctors to garner access to important information
for their patients at point-of-care. We are now at the right place at the right time, facilitating critical and timely communication
between life science companies, physicians and patients. Our results also reflect how we have made great strides with innovation
during the pandemic, and particularly with the launch of TelaRep, our new virtual communication solution. This cloud-based solution
enables providers to reach the right pharma contact from within their EHR work flow with just one click, helping fill the communication
gap created by limited face-to-face interaction due to COVID. In fact, last December <I>PM360 Magazine</I> recognized TelaRep as
one of the most innovative solutions for Life Sciences, very proud of that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to existing solutions in the
platform, we are now leveraging real world data to deliver real time information at the point-of-care with our new AI-powered real-world
evidence solution. Our sophisticated proprietary algorithms that power this solution also enable us to derive additional revenue
from our existing network. Over the last year, we&rsquo;ve continued to shift our business model toward enterprise level engagements
with recurring revenue streams by leveraging the trust we built with our clients over the last several years. Client renewal rates
at the end of 2020 reached an all-time high, all while adding 60 new brands to our platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRX Corporation - Fourth Quarter and Full Year 2020 Conference Call, February 24, 2021</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We&rsquo;ve also found that we can help to digitally
commercialize new products for pharma at a time when face-to-face sales are virtually impossible; that is, no visiting reps, industry
conferences or in-person presentations. This supports an ever expanding available market and tremendous growth opportunities. Our
solutions are now providing essential communication pathways for pharma to connect with physicians and patients through the patient
journey with a focus on affordability, access and adherence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our digital health footprint continues
to expand with more pharma clients on-boarding onto our platform and we are working relentlessly to steward health data in ways
that can effectively yield better outcomes for all the stakeholders, and especially for the millions of patients who are connected
to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now before I go further, I&rsquo;d like to turn
the call over to our CFO, Doug Baker, who will walk us through the financial details for the fourth quarter and year. Doug?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Douglas Baker</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Will, and good afternoon, everyone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Earlier today, we issued a press release
with the results of our fourth quarter and full year ended December 31, 2020. A copy is available for viewing and may be downloaded
from the Investor Relations section of our website. We expect to file our Form 10-K with our full results in the second week of
March.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now turning to our financial results for
the fourth quarter and full year 2020. Our revenue for the quarter totaled a record $16.4 million, which was up 123% compared to
the same year ago quarter. Our revenue for the full year increased 76% to $43.3 million, driven almost entirely from organic growth
of our core solutions and patient engagement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gross margin for the fourth quarter totaled
$8.6 million, which was nearly double that of a year ago. Gross margin for the full year was $24.1 million up from $15.4 million
in 2019. For the quarter, our gross margin percentage came in at 52.4% versus 60.6% a year ago. For the full year, it was 55.7%
versus 62.8% in 2019. This lower percentage in Q4, which impacted the full year as well, was the result of our solution mix. Much
of the incremental business that came in Q4 was related to lower margin solutions that were very easy to launch and fulfill in
short time periods. Even though our gross margin was lower, this incremental business almost all falls to the bottom line, which
demonstrates the leverage in our model. Looking ahead, we expect our margins to remain in the 56% to 58% range in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operating expenses increased to $7.2
million in the fourth quarter of 2020 compared to $6.8 million in the same year ago period. This is almost all the result of variable
expenses associated with the added revenue. However, even though our revenue is up over 100% for the quarter, operating expenses
were up less than 10%, once again demonstrating the substantial leverage of our model. Operating expenses for the full year of
2020 increased to $26.2 million, compared with $19.1 million. The increase in operating expenses in both periods were largely due
to the scaling up of our operations to support continued customer and solution growth, including additional staffing as well as
a full year impact of the acquisition we made in late 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">GAAP net income for the fourth quarter
of 2020 was $1.4 million or $0.08 per fully diluted share, compared to a net loss of $2 million or $0.14 per share in the same
year ago period. Net loss for the full year of 2020 totaled $2.2 million or $0.15 per share, which improved by about $900,000 from
a net loss of $3.1 million or $0.23 per share in 2019. Our non-GAAP net income in the fourth quarter of 2020 was $2.7 million or
$0.16 per fully diluted share, which compares to a non-GAAP net loss of $400,000 or $0.03 per share in the same year ago period.
Non-GAAP net income for the full year of 2020 was $3.2 million or $0.20 per fully diluted share, compared to non-GAAP net income
of $900,000 or $0.07 per fully diluted share in 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRX Corporation - Fourth Quarter and Full Year 2020 Conference Call, February 24, 2021</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now, turning to our balance sheet, cash
and cash equivalents totaled $10.5 million at December 31 compared to $12 million on September 30, 2020. Earlier this month, we
raised $71 million in an equity offering. We plan to use these funds to further expand our business and accelerate revenue growth.
Our receivables are very high quality because of our customer base. They continue to pay regularly and predictably, and our day
sales outstanding continues to be constant. We remain debt free and do not anticipate needing to raise additional capital in the
near future, either for operating purposes or to fund our growth. That wraps up the discussion of our financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now I&rsquo;d like to turn the call back over
to Will. Will?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Doug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Today more than ever OptimizeRx is evolving
into the nation&rsquo;s critical communication platform for patients, physicians and life science companies. Bold statement, but we&rsquo;re
really living it. Like no other digital health platform in the market, we deliver important information in real time at the point-of-care
right when clinical decisions are being made. We have access to tens of millions of patients and most physicians, as well as the
technology, compliance and operational support to continue to play a major role in the ever evolving digital health market. Our
partnerships with EHR and e-prescribing companies enable us to augment that physician workflow with actionable insights by providing
additional real time critical information to clinicians who are dealing everyday with complex healthcare scenarios. We can improve
the patient and physician experience and ultimately treatment outcomes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As Doug mentioned, over the last year,
we&rsquo;ve continued to expand our team in preparation for the growth opportunities ahead. We&rsquo;ve enhanced our Leadership team across
financial, legal compliance and strategic planning. To help us unlock more reach into our client base, recently Angelo Campano
joined us in November of 2020 as our new Senior Vice President and Principal of Agency Channels. His experience with developing
partnerships that bring digital touch points together at the point-of-care greatly complements our mission of helping life sciences
be present through that care journey. You might have noticed in the press release we saw Angelo&rsquo;s name in <I>MM+M</I>&rsquo;s 40
Under 40 and it&rsquo;s just a positive thing for our Company. It&rsquo;s perhaps not surprising that we&rsquo;re seeing immediate results from his
efforts that will positively impact our growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We had a great start to the year and remain
focused on key growth drivers of land and expand within our clients, selling our platform solutions across brands, and connecting
more doctors to more patients. We see our real world evidence solution accelerating all of this by a factor in a way that works
for everyone involved. We are however very much looking at enhancing our reach to certain therapeutic areas of additional patient
populations. We continue to be focused on unlocking access to patients via our channel partners as a differentiator with the patient
engagement solutions. The funds from our recent equity raise will be used to invest in our current platform, fund continued innovation,
open additional M&amp;A opportunities, and further solidify our market dominance in this space. It was clear from those who participated
in the raise that our story is very understandable, defensible, and scalable, all while still being very early in our evolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRX Corporation - Fourth Quarter and Full Year 2020 Conference Call, February 24, 2021</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2021, we expect to see a continued favorable
shift to higher margin recurring-revenue enterprise deals, and we believe our pipeline growth has been driven by a permanent shift
to more digital enablement. We have 46 enterprise engagements in our pipeline as we start 2021, valued at more than $50 million,
a significant increase over this time last year, and we expect that to continue to grow inside this year. This breaks down to about
31 potential deals valued at up to $0.5 million, 11 up to $3 million, and four, $3 million or over. This does not include several
that have already closed in all of the above ranges, including the $3 million-plus. It&rsquo;s safe to say our shift away from tactical
towards enterprise engagement is being very well received by our clients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For all those prospective engagements,
we expect to realize our traditional annual closing rate of between 35% and 50% over the course of the year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of this represents great progress.
When adding in the in-year buying and year-end buyer potential, we see another year of strong growth ahead. As we continue to invest
in innovation and enhance the scalability of our technology and commercial teams, we believe we have the momentum at least aspirationally
to reach $100 million revenue run rate with the clients, network and team we have today. Deloitte recognized OptimizeRx as one
of the top 500 fastest growing companies in North America. We expect to remain on that list.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now with that, we&rsquo;d like to open up to
your questions. Greg.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you very much, sir. All right, and
first from William Blair, we have Ryan Daniels. Please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ryan Daniels</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, thank you for taking the questions,
and congrats on the strong performances here.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Will, you talked a little bit about the
need to drive more preventive care going forward because of similar lapses that occurred during COVID, and people avoiding offices
or office shutdowns. Can you talk a little bit more about your patient engagement platform and some of the things you can do to
help doctors generate that revenue stream? Number one.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Then number two, as that revenue stream
comes in, does that also have a multiplier effect on your core messaging business? Because, they&rsquo;re in the office and the doctors
will start receiving some of the marketing branding campaigns as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sure, yes. Hi, Ryan, thanks for the question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The first part, we strategically decided
that you really have to look at the benefit, the ultimate beneficiary of everything we&rsquo;re doing, which is the patient. As everyone
knows, about two years ago, we, through two acquisitions, we bought the technology that enabled that, one, to connect directly
to the mobile, but frankly, to deliver content to patients any way they want. While that&rsquo;s a crowded space, we liked it because
we were one of the only ones that had such a broad network of physicians.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unlock here potentially, which is a
tool to facilitate less meetings between doctor and patient, not more, is the ability for a doctor to enable a patient right in
the workflow to join an adherence or compliance program, which really helps the patient understand the medication treatment, both
emotionally and intellectually. It also helps them afford it because we can obviously attach any kind of savings that is available
for that same communication, and it&rsquo;s right on the mobile. So that answers a little bit your second part of the question, that
aside from just the unlock, we feel is coming.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRX Corporation - Fourth Quarter and Full Year 2020 Conference Call, February 24, 2021</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The other piece of it is it drives some
of our core messaging solutions that physicians enable today in just another format, which help patients afford their medications,
which is obviously a very large issue in the market, certainly with many people being disrupted from work. That&rsquo;s even more important
today than it was a year ago.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ryan Daniels</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay, that&rsquo;s helpful color. And then one
thing you highlighted, both via press release intra quarter and then in your comments, is kind of your investments you&rsquo;ve made
in artificial intelligence and machine learning. I&rsquo;m curious if you can talk a little bit more about how that actually changes
the deployment of your solutions and integrates into the physician workflow to kind of make it a smarter technology for both your
patients and your provider partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, I&rsquo;ll start and then I&rsquo;ll ask Steve
to jump in, because he&rsquo;s driving this effort.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you think about what we&rsquo;ve been doing
today, the triggers were fairly straightforward: disease code, some search functionality around the patient. But there&rsquo;s just so
much more data available today, from a real world based evidence, which allows you to be smarter with how you message and what
creates the message. So where are we may have had one trigger, maybe two, we may have four or five now that allow us to deliver
the right information to the doctor at the right time based on the profile of that patient they&rsquo;re seeing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It&rsquo;s just something that our clients have
been looking at RWE for years, using it for training, to drive marketing, messaging, but rarely have they been able to use it to
actually directly connecting to point-of-care in a way that doesn&rsquo;t require someone to remember something; hence, the machine learning
algorithm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Steve, maybe you can give a little more
color from the client perspective on that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Steve Silvestro</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, I think you did a good job there,
Will.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hi, Ryan, good to hear from you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The only thing that I would add to what
Will has already said is that what this allows us to do is to plug into the broad ecosystem of these massive real world evidence
databases; and you saw the announcement on Komodo, there will be some other subsequent announcements pending. Obviously, we&rsquo;ve
got a partnership with EVERSANA, they&rsquo;ve got a great repository of data as well. But what happens essentially, we have access to
patient records that are longitudinal and historic in nature, and that will be refreshed real time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The algorithms can train on that history
at the patient level, roll up to a physician level, and they can begin to be predictive in nature, Ryan. So you can start to understand
the patient is tracking toward a positive diagnosis like diabetes. We can do preventative messaging that physician, helping them
understand that they should contemplate or think about wanting some certain tests, etc., to intervene and help that patient in
different ways.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">That kind of comes back to the question
that you had asked previously around patient engagement, linking this in there, and also helps in a preventative way. But it essentially
connects us to the broader ecosystem. As you heard Will say, it&rsquo;s a force multiplier around messaging, because our messages have
been limited up until we did this to whatever we could see inside the ecosystem of connection that we have. Now it&rsquo;s the entire
healthcare record across multiple repositories of data with all of these patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRX Corporation - Fourth Quarter and Full Year 2020 Conference Call, February 24, 2021</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ryan Daniels</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Great, that&rsquo;s very helpful color. Maybe
last one for me. Just thinking about the $180 million of pipeline opportunity, with strengthened close rates, the move towards
digital marketing, for manufacturers in general, obviously the right opportunity for you to capitalize on. Can you talk a little
bit more about what you anticipate from a SG&amp;A spend perspective in 2021, as we think about, in particular, sales and marketing
investments, whether it&rsquo;s direct sales force, or just other kind of digital or brand marketing capability for the organization
to grow and to drive awareness of your offering? Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, thanks, Ryan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think as people digest what they&rsquo;re seeing
in Q4, I want to just mention two things. One, this Company clearly has tremendous leverage in SG&amp;A given, though we don&rsquo;t
generate content, we are a tech Company and we facilitate connections through our network. So you should not expect heavy growth
in SG&amp;A as we continue to scale the business. We will selectively add in areas that make sense like we did before with a couple
of people.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When you&rsquo;re growing like this and you&rsquo;re
in the right place at the right time, you can be highly selective with people; so, we really feel honored to have that position
and are able to get some terrific people on board. You should not expect dramatic, you should continue to see leverage as we scale
through the year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ryan Daniels</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Great, thank you and congrats again.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Ryan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All right. Moving on. Our next question
is going to come from Andrew D&rsquo;Silva with B. Riley Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Andrew D&rsquo;Silva</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks for taking my questions, and congrats
on the progress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A lot of my questions were just touched
on, but just to start, obviously, the fourth quarter saw a very significant increase in just a seasonal spend across your platform.
I&rsquo;d be very interested if you could just can discuss what you learned as it relates to your platform&rsquo;s ability to scale just
based on that? Then maybe you could just tie that in with a little bit more color on how that translates to the operating leverage
that you&rsquo;re seeing, and talk about how that looks going forward?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRX Corporation - Fourth Quarter and Full Year 2020 Conference Call, February 24, 2021</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Andy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, I&rsquo;ve been in the pharma world for
over 20 years; Steve has as well. And you just know, in Q4, there&rsquo;s always some magic that comes your way. The fear is that magic
is something you can&rsquo;t do, because that&rsquo;s just very frustrating. One of the reasons why I love this business so much is we can
turn on a dime and react to our client&rsquo;s needs on really important stuff, like taking real clinical messaging, financial assistance,
patient engagement, and enabling it very quickly, based on activity, at point-of-care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Q4 was an example of good buy up; as a
matter of fact, we saw higher buy up than we traditionally see. I think we can safely say that there was excess budget because
of some of the lack of spending on direct visits and conferences. But the good news is, we were able to capture every dollar that
we were asked to. As you can see in the P&amp;L, as Doug referenced in his section, the leverage streams through. That will hold
through as we go forward. It is not something we have to stop, build, adjust, call our partner. It&rsquo;s very simple. Obviously,
we&rsquo;ve been working really hard as we&rsquo;ve been growing to make sure the team is right, the tech is scalable, and is compliant and
secure. So feeling really good about that leverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Andrew D&rsquo;Silva</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay, pretty useful color. Really interested
in your insight in the pipeline. Just curious if the cadence from RFPs coming in and contracts being awarded is following what&rsquo;s
historically been seen. Or if you expect to see off cycle RFPs and contract awards come in similar to what you saw last year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well, I&rsquo;ll say a little bit and then pass
it to Steve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There&rsquo;s obviously always seasonality to
pharma as they start a little slow and build up and you look at the first half, and you can definitely look at a bigger second
half traditionally. We have seen a stronger start this year, which is great. I think that&rsquo;s a testament to the enterprise type
deals we have, our renewal rates, the team, the operational team, just the account managers are exceptional, being very connected
to both the clients and anyone that supports the clients. I see a similar profile to last year, just more business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Steve, you want to comment anything on
there?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Steve Silvestro</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, I think that&rsquo;s right. The only addition
that I would make is one of the other pieces that we&rsquo;ve seen sort of accelerating business for us are as pharmas pivot a little
bit from using in the field physical reps and looking for different ways to reach physicians. I think you probably saw the Pfizer&mdash;not
Pfizer announcement, excuse me; the Amgen announcement. There will be similar announcements that will follow, whether they&rsquo;re public
or that&rsquo;s just being done without actual announcements. But those broad sweeping layoffs or reductions are going to happen. So
of course, those funds are redeployed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">That is also strengthening the case of
the business because we do have an ability, as Will has said, to reach the physician that pharma wants to speak to and to communicate
those messages. We can do it in real time, which is essentially better than putting a physical representative in front of the physician.
It&rsquo;s less disruptive, it&rsquo;s more organic and germane to what they do. Of course with TelaRap, if they still need to speak to a physician,
they can just hit the button and reach back out, speak with the rep. So for that reason, I think that&rsquo;s also helping to accelerate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRX Corporation - Fourth Quarter and Full Year 2020 Conference Call, February 24, 2021</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Andrew D&rsquo;Silva</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">That&rsquo;s a great point I wasn&rsquo;t necessarily
thinking about, but useful context nonetheless.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Then the last question I have is related
to the $180 million-plus pipeline numbers that you noted in your prepared remarks. Is that net of contracts already awarded, or
is that a gross or cumulative number?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">That is net of.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Andrew D&rsquo;Silva</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay, great. Well, hey, thank you very
much, it&rsquo;s very useful context. And the best of luck going forward.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks so much. Thanks, Andy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moving on. From Lake Street, we have Eric
Martinuzzi.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Eric Martinuzzi</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hi. My congratulations on Q4 as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I want to dive into the Q4 gross margins.
That 52.4% was certainly below what I was modeling. I know you said it was due to the change in solution mix. I know years past,
sometimes in Q4, you are either re-upping or trying to win new distribution business. Does that have anything to do with it, or
is it really more product choices?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. Hi, Eric.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All about solution mix, I think that&rsquo;s
what it is there. The beautiful thing about our business is that&mdash;you&rsquo;re hearing this theme, it&rsquo;s just the leverage, right.
We&rsquo;re not concerned about the gross margin. We know how to manage it. A lot will be driven off activity. We still feel over
time that continues to improve. But if there is ever a chance to bring in the revenue and execute it for our clients, as needed,
we will do that. That&rsquo;s what you saw in Q4, just the heavy, heavy ask around some of the legacy solutions and legacy partnerships,
which have a higher rep share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Eric Martinuzzi</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay, and then is this something, just&mdash;you
talked about kind of Q4 seasonality. Is this something we should anticipate in our models? So if you&rsquo;re telling us gross margins
are going to be 56% to 58% over the course of the year, should we just naturally be anticipating sort of that, I don&rsquo;t want to
call it budgets slush, you have a better term for it, the buy in, is that just kind of model for buying in Q4 again longer within
that?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRX Corporation - Fourth Quarter and Full Year 2020 Conference Call, February 24, 2021</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, I think you can go with the ranges
we gave annually. If these sway 1% or 2% either way, it&rsquo;s not going to be material. Obviously, if they are going up, that&rsquo;s great
for everyone; if they&rsquo;re going down, that means the top is growing. I think just taking that sort of directional guidance, or aspirational
guidance towards that range is plenty for models, both for you and investment community.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Eric Martinuzzi</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay, and then speaking of aspirations,
I noticed you didn&rsquo;t give us a year in which you&rsquo;re going to have $100 million in revenue. So we&rsquo;ve got a potential revenue of
$100 million. I just wanted to dive into that, you have talked about a shift to more subscription type revenue or current type
revenue. In this year where you do achieve that $100 million in revenue, what percentage is subscription?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oh, that&rsquo;s a good question. I mean, I would
think we&rsquo;re at least half if not more in terms of enterprise, we call that enterprise, right? That&rsquo;s contracted nature, 12 months,
very recurring. I think that would be our goal. Yes, we don&rsquo;t give guidance, so we don&rsquo;t put a date on it. I think what&rsquo;s more
important is we have the team to get there, aside from maybe a few select hires; so that should scream, we&rsquo;re going after it hard.
There&rsquo;s that leverage we keep talking about.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Eric Martinuzzi</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay, the last one is for Doug on the operating
expense side. I was actually thinking Opex was going to be a little bit higher in Q4 that it turned out to be. I think you came
in at $7.2 million. What should we be thinking about either for full year or Q1 if you wanted to just focus on the near term here
as far as operating expense here?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Douglas Baker</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I would say, if we look at the full year,
absent us deciding to make some larger investments in growth, you should see no more than 10% growth in Opex. You could even see
some declines in Q1 from the $7.2 million because there is a little bit of relationships to revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Eric Martinuzzi</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. Just a last housekeeping item here.
The share count we should be using for Q1 given the raise, can you give me a cheat sheet there?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Douglas Baker</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You could add somewhere in the 16.8 million,
something like that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Eric Martinuzzi</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. Congrats again. Thanks for taking
my question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Douglas Baker</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Eric.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All right, moving on. From RBC Capital
Markets, we have Sean Dodge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRX Corporation - Fourth Quarter and Full Year 2020 Conference Call, February 24, 2021</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Thomas</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hi, good afternoon. This is Thomas (phon)
coming on for Sean. Thanks for taking the question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Just kind of going back to revenue growth,
a lot of momentum here. Is there any way to kind of unpack how much of a tailwind COVID was for you in 2020, or even into the 2021?
I guess, kind of when we look ahead, is there any sense you can give us, just thinking kind of a more sustainable, longer range
trajectory curve should be?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, so we&rsquo;ve talked about it a little
bit in Q3. We didn&rsquo;t feel like we saw any revenue after Q3 from COVID. We saw a lot of internal referral, we saw a lot of learning,
a lot of exploration. Clients tend not to move quickly on these things, they digest it. Q4, though, I would say we saw a couple
million additional buy up just from budget, excess budget. Going forward, I think because of this shift, ourselves, we&rsquo;ve got big
expectations to keep growing this business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;ve always said, there&rsquo;s a 25% to 30%
growth is&mdash;there&rsquo;s so much room for us that that is that is achievable, and feel like we&rsquo;re not doing our job if they&rsquo;re not
doing that or beating it. We don&rsquo;t give the guidance. But I think given all these things we mentioned between our&mdash;we&rsquo;re really
embedded well in the clients, there&rsquo;s tons of whitespace there. We&rsquo;ve got the solution set, that&rsquo;s critical. We&rsquo;ve got the reach
today. Obviously, we&rsquo;re always looking to augment that. I would say we&rsquo;ll feel just overall macro tailwinds. This year will continue
to be disruptive for pharma. I think both Eric and to your question, as we get to the end of the year, there probably will be additional
excess budget as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Thomas</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">That&rsquo;s very helpful, thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I have one more on physician reach. You
had mentioned integrations now helping you get to 60% of docs. Is that kind of a fully penetrated number there, or there are kind
of more EHR platforms you think you can add to get to an even higher proportion? Are you feeling closer to that kind of 90% daily
EHR users you guys reference?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, for us, as we shifted to largely specialty
medications, which are smaller populations, harder to reach both physician and patient. It&rsquo;s less of a volume game for us at this
point. It&rsquo;s really fine tuning the network and finding areas where if we added reach it would immediately add revenue and provide
solutions for our clients. We&rsquo;re really focused on that. We&rsquo;re not focused on going after the big numbers. There are plenty
of EHRs still that we&rsquo;re not fully integrated into. Of course, we work on those every day. But I think the important takeaway is
we&rsquo;re not reliant upon that. If you see analysis come through, I would focus in on therapeutic areas because obviously that&rsquo;s a
bigger unlock for us in terms of revenue potential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Male Speaker</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay, that makes sense. Very helpful. Thank
you, and congrats on the quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRX Corporation - Fourth Quarter and Full Year 2020 Conference Call, February 24, 2021</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All right. Then moving on, ladies and gentlemen,
from Venetor Capital, we have Brandon Osten has our next question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brandon Osten</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hi, Will. How you doing, guy?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hi, Brandon. Good to hear from you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brandon Osten</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good to hear you, man.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I know you guys don&rsquo;t guide, so I just
wanted to sort of work around what you guys have put out there. In terms of your sales breakdown, right now, roughly how much of
your quarterly revenue at this point are enterprise SaaS recurring versus messaging? What kind of run rate you guys running at
right now if we sort of bunch everything that isn&rsquo;t volume dependent?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, it&rsquo;s a good question. It&rsquo;s a fair
question. We&rsquo;ll be able to dive into that a little bit better for 2021 based on reporting Q1, right, because we&rsquo;ll have had
a lot of conversion by then. We can look at percentages. But it&rsquo;s around 50%. It&rsquo;s right now, based on last year. It makes sense,
right? I mean, for our clients, why would they do this? It&rsquo;s multiple solutions. So it takes them working with maybe a few other
providers that just work with us. It&rsquo;s one measurement. The measurement tends to be in terms of the ROI. It&rsquo;s exponentially better
when you just have more outreach to the same patient and physician populations through one platform, and you can watch prescription
behavior. I would expect it&rsquo;ll be there for a while, and then hopefully tip heavier as we get more and more people on board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brandon Osten</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Right, and if I look at 2019, I would assume
that it was less than 50% at that point, because this is not a completely as much. So basically, the enterprise SaaS non-messaging,
non-volume independent part of the business is clearly growing over 100%. Is that safe to say?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">That part? Yes. That&rsquo;s safe to say. It&rsquo;s
not&mdash;there is still a volume dependency in some of this. It&rsquo;s not 100% pure billed monthly. Thank you very much. It&rsquo;s still
I think it&rsquo;ll move that way more and more over time. So that&rsquo;s the only thing I would carve out from that statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brandon Osten</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The point is, if I&rsquo;m trying to sort of
interpret your pipeline, your pipeline comments, your $180 million, the enterprise is $50 million. Is that&mdash;when you&rsquo;re
talking about the pipeline enterprise, is that all additive to the current run rate of enterprise sales right now? Like if you
guys executed on $50 million of enterprise, all $50 million obviously, won&rsquo;t, but all $50 million of enterprise sales, would that
be additive to your current run rate? Or does your current run rate include&mdash;I guess is that pipeline include renewals or
something?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRX Corporation - Fourth Quarter and Full Year 2020 Conference Call, February 24, 2021</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, no, it&rsquo;s not additive. It&rsquo;s unique.
It&rsquo;s the full year again, it&rsquo;s not additive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brandon Osten</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It&rsquo;s not. So sorry, when you say it&rsquo;s not&mdash;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The run rate is part of that, yes. That&rsquo;s
(multiple speakers).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brandon Osten</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The run rate is part of the pipeline. Yes,
okay. That&rsquo;s in terms of the pipeline, so this is included as part of the pipeline?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, it is. That one (multiple speakers)
includes, its $50 million right now of enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brandon Osten</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Right. But if you closed on $180 million
of pipeline, your revenues, your current run rate of revenues would go up something less than $180 million. Is that maybe a good
way of framing? If you closed $180 million then your revenue would be whatever you did last year plus $180 million?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No, no. It would be&mdash;it doesn&rsquo;t go
on top of a run rate. It is the total (multiple speakers) going after for the year, yes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brandon Osten</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay, not going after for the year. Okay,
great. Okay. All right. That&rsquo;s great for now. I signed up to speak to you at one of our conferences in the near future. I&rsquo;ll
follow up there. Perfect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Talk to you soon. Thanks. Yes. Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All right, moving on. From Poptech LP we
have Harvey Poppel. Please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRX Corporation - Fourth Quarter and Full Year 2020 Conference Call, February 24, 2021</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Harvey Poppel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, Will, great job. Congratulations.
As you know, we&rsquo;ve been following for many, many years. This has really been a blowout quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I just want to make sure that I&rsquo;ve got
this right that you just reported numbers that were actually higher than what you pre-announced only a month ago. In other words,
you went from $16 million to $16.4 million in terms of fourth quarter revenue, and your pipeline went from $170 million to $180
million, that&rsquo;s up about 6% just in one month. Is that&mdash;have I got it right?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">That is right. It also includes us closing
some business, which we won&rsquo;t tell you what it is, but that certainly means there was probably greater than a 6% increase in the
pipeline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Harvey Poppel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All right. Getting back, I know you&rsquo;ve
had a number of questions on this, but I&rsquo;m going to come at it from a different direction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To interpret the pipeline and try to understand
its ultimate effect on revenue, if one were to simply take 35% to 50% and multiply by $180 million you get $63 million to $90 million.
Is that implied, the range of revenue that you might be able to achieve this year? Or is there something about the $180 million
that takes us out much further?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, we talked about that in Q3. The pipeline
is generally 18 months view. So it&rsquo;s not apples to apples, it&rsquo;s a little bit of a spillover into 2022. You need to give a little
bit to that maybe four to six months into next year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Multiple speakers).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Harvey Poppel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. Lastly, on the new cash that you&rsquo;ve
been able to raise&mdash;and you&rsquo;ve mentioned in the course of raising and then again today that M&amp;A is part of that. Is there
a sense in your M&amp;A strategy at this point of whether that&rsquo;s earmarked to just one or two large deals, or is it more likely
to be a whole series of much smaller deals?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;ll start and then I&rsquo;ll ask Miriam to
chime in, because she&rsquo;s going to be running point for us on that effort.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No, I think we feel very sufficient with
technology, sort of startup technology add ins. If we&rsquo;re going to do something we want to have it be more substantial and accretive
inside our guardrails just because of the effort that it takes to do those.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Miriam, why don&rsquo;t you add a little
bit of color to that, if you don&rsquo;t mind?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Miriam Paramore</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay, sure. Hi, Harvey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRX Corporation - Fourth Quarter and Full Year 2020 Conference Call, February 24, 2021</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have a number of opportunities that
we&rsquo;re looking at. It is as easy to buy, or as easy or as hard to buy something big as it is to buy something small. So without
knowing because a little bit of it&rsquo;s opportunistic, and everything is timing, as you know. We think we&rsquo;ve got a good filtering
process, we&rsquo;ve got a number of opportunities we&rsquo;re looking at. We&rsquo;ve got some that we&rsquo;ve kind of pointed out. But I think we prefer
something a little a little more substantial without&mdash;nobody has a crystal ball, Harvey. But we certainly don&rsquo;t need to buy
anything that&rsquo;s infrastructure related or that improves our test base, because we&rsquo;re really pretty solid there. But anything that&rsquo;s
innovative, that&rsquo;s additive, we want to we want to look at.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Harvey Poppel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Great, thanks. Thanks a lot. I&rsquo;ll
step aside. Congratulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Harvey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All right. Then moving on, we have Ron
Chez (phon) next up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ron Chez</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good afternoon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good afternoon, Mr. Chez.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ron Chez</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So somebody already&mdash;or you commented
about $100 million aspirational goal. So that&rsquo;s not aspirational for 2021, right? I mean, that&rsquo;s out, that&rsquo;s it, you don&rsquo;t
want to do that in 2021?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oh, no way, why would I&mdash;no why would
I want to do that? The point of that number is we absolutely have the team to do it. We&rsquo;ve got the reach to do it. We have clients
who have certainly plenty of appetite to do it. But I would never commit to that guidance. This is really, I think, to give our
Investors and future Investors just a glimpse that, one, it&rsquo;s really early, two, we&rsquo;ve got the current infrastructure to
get there. We all want it to happen faster, always. We&rsquo;re a pretty aggressive group. But we can see we&rsquo;ve got the team to do it,
which is really exciting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ron Chez</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So given the market and customers, this
is still early innings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oh, yes. Steve can comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think that we were seeing really good
adoption. It wasn&rsquo;t the early believer sell anymore (phon), even pre-pandemic. But post pandemic, you&rsquo;ve had massive internal referrals
for us. Just more awareness in the corporate setting of digital enablement. We all use Zoom a lot. That trickles into marketing.
Then doctors and patients are just more attuned to using technology to help maintain their practice, or patients just manage their
lives, basically.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Steve, maybe you can comment to the client
side.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRX Corporation - Fourth Quarter and Full Year 2020 Conference Call, February 24, 2021</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Steve Silvestro</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, sure. Hi, Ron.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Part of the growth that you see in the
numbers that we&rsquo;ve talked about, obviously new brands is critical, but incremental gains in enterprise is clients that might have
already climbed on the platform scaling up to other solutions towards point and so as that continues to go, with the large number
of brands that are on, they&rsquo;ll scale up to the different solutions on the platform by brand, but they&rsquo;ll also do that at
a disease level. In many cases where brands are operating four or five, six different diseases, that represents 60 different programs
for OptimizeRx. So there&rsquo;s tremendous interest, it&rsquo;s very early, there&rsquo;s tremendous whitespace for us to go out and continue to
capture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ron Chez</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. One other aspect of growth is number
of EHRs and HCPs. You want to comment on that at all?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think we&rsquo;ve covered a lot of it. I think
the key is focusing in on these specialty therapeutic areas, like oncology, which will dominate the marketing spend for a decade.
So we&rsquo;re really focused in on that; at this point, it&rsquo;s a fine tuning, it&rsquo;s not a volume game. We, by the way, have a lot of capacity
in our existing network. So when we talk to whitespace, on the brand side, we can also say the same thing on the reach to physicians.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think our partners through this change,
you can imagine what they&rsquo;re going through adding telehealth and all sorts of services. I just think there&rsquo;s a really good atmosphere
for collaboration and patient at the channel level. We really, I think, do a great job being collaborative and innovative with
them. So expect some good things there this year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ron Chez</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you for your efforts. Keep grinding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Ron. We will. Thanks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All right, folks, moving on. The last question
we have in the queue is from Sid Kapoor with Silver Mount Capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRX Corporation - Fourth Quarter and Full Year 2020 Conference Call, February 24, 2021</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sid Kapoor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hi, Will, good afternoon to you. Just two
quick ones from me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Firstly, would it be fair to say that the
patient engagement piece is the key driver of ROI for pharma companies? Would you say that&rsquo;s what&rsquo;s driving the shift in customers
from a patent drug to an enterprise contracts model? That&rsquo;s the first question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The second question is, in terms of your
addressable market or your serviceable addressable market, do you believe that this extends beyond branded patented drugs? Or rather
how do you think about this from a patented versus not patented perspective? Thanks a lot.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sure, Sid, good to hear you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I would not say that patient engagement
is driving, by itself, the shift to enterprise deals. I think, just to remind everyone, when we about two years ago decided to
really focus in on the patient journey, and the critical places to reach doctors and patients along that for our clients, patient
engagement is certainly a critical piece of it. It&rsquo;s one we can all kind of relate to as people, patients and consumers of healthcare.
But the awareness, the amount of drugs coming to market, and the amount of interactions between those drugs, whether they&rsquo;re branded,
or branded with generic, is complex and it&rsquo;s really hard to keep up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What&rsquo;s really driving enterprise
is, one, it&rsquo;s just easier to buy more from the same company, so we do that; two, we have more touch points than anyone in the market,
relative to getting information inside of the workflow at point-of-care for doctors, and then have a wonderful way to stay with
the patient and help them understand and afford the medication. So it&rsquo;s not the sole driver of patient engagement, but it&rsquo;s definitely
a piece of it. It&rsquo;s why we did it strategically.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Relative to TAM, the total available market,
brand is the majority of our revenue. You&rsquo;d see companies like GoodRx and RxSense helping people get discounts on any product,
really getting that down to a transparent level, even picking the pharmacies you should go to. So we need we really like that.
It brings awareness, transparency, doctors are more aware that there&rsquo;s discounts available, consumers have certainly this whole
consumerism trend. While we are largely a B2B type Company, any awareness at the consumer level helps drive awareness for what
we do.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I do think it along with just the expansion
of things like telehealth have largely expanded our total available market and opened the eyes to pharma and others that this is
a really good channel to connect and share and help deliver the right information at the right time. So, yes, great questions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sid Kapoor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Will. Actually I have a couple
more, but I think I will do them offline, but thanks very much.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Great. Have a good night.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All right. Everyone, at this time, it does
look like that concludes our question-and-answer session. I&rsquo;d now like to turn the call back over to Mr. Febbo. Please go ahead,
sir.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRX Corporation - Fourth Quarter and Full Year 2020 Conference Call, February 24, 2021</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well, thanks to everyone for joining the
call today. We hope your main takeaway from our discussion is the understanding of our ability to generate tremendous value for
Shareholders and everyone involved. That this is thanks to our strong organic growth, our sustainable competitive advantage and
our favorable market timing. But beyond all the numbers, we hope you appreciate that we continue to foster a unique culture, one
dedicated to do something truly valuable and which will make a difference in people&rsquo;s lives, from patients to physicians and beyond.
We do not provide guidance as an early stage public company and especially in this current environment. But given everything you&rsquo;ve
heard today, we hope you&rsquo;re optimistic as we are as we navigate this transformative period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now with that, let&rsquo;s wrap up the call.
Good night. Thanks, Greg.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All right. Thank you, sir.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before we conclude today&rsquo;s call, I&rsquo;d like
to provide the Company&rsquo;s Safe Harbor statement that includes important cautions regarding forward-looking statements made during
today&rsquo;s call. Statements made by Management during today&rsquo;s call may contain forward-looking statements within the definition of
Section 27A in the Securities Act of 1933 and amended&mdash;excuse me Section 21E at the Securities Act of 1934 as amended. These
forward-looking statements should not be used to make investment decisions. The words anticipate, estimate, expect, possible and
seeking and similar expressions identify forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">They may speak only to the date that such
statements are made. Such forward-looking statements in this call include statements regarding estimation of total addressable
market size, market penetration, revenue growth, gross margin, operating expenses, profitability, cash flow, technology investments,
growth opportunities, acquisitions, upcoming announcements and the need for raising additional capital. They also include the Management&rsquo;s
expectations for the rest of the year and adoption of the Company&rsquo;s digital health platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company undertakes no obligation to
the publicly&mdash;excuse me publicly update&mdash;to publicly update or revise any forward-looking statements, whether because
of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties,
some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth
in, contemplated by or underlying these forward-looking statements. The risks and uncertainties to which forward-looking statements
are subject to include but are not limited to the effect of government regulation, competition and other material risks. Risks
and uncertainties to which forward-looking statements are subject to could affect business and financial results are concluded
in the Company&rsquo;s&mdash;or excuse me are included in the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December
31, 2019. This Form is available on the Company&rsquo;s website and on the SEC website @sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before we end today&rsquo;s conference, I would
like to remind everyone that this call will be available for replay starting later this evening, running through March 17. Please
refer to today&rsquo;s press release for dial-in replay instructions available via the Company&rsquo;s website at www.optimizerx.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you for joining us today. This concludes
today&rsquo;s conference call. You may now disconnect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">18</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide
an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference
call. This transcript is being made available for information purposes only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1-888-562-0262 1-604-929-1352 www.viavid.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  Y 2P# 2(  A$! Q$!_\0
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MM9AN]2^'GBFX\ >+-3TI;RWTE'_V ?@5\;?AK^TE\&_AG\?/@[XDM?%_PO\
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M4T>_U_7K^VTW5-8FL=)TRW>[O[Q=,T2RU'5KT6UM'),\-A8W5P8T9DB8*:^
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M$O?"_B34770=)\2^%]>U'71>:?KKZ?8>(M(UX3+KNG7GAJSTW7_T_P &\OX
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M69F("JH&2S$X   )))P!R:_R&_\ @H;XUT+]MG_@Y#\<:C^SQ?6OB#3OB/\
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M[3Q!I%W=^"O$FN"+S;[6=(NWO(9A FG/86%G:6$/Z044 ?"&K_\ !/#X$3?
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
